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EDITORIAL
Central Nervous System Immune Surveillance
On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
M ULTIPLE SCLEROSIS (MS) IS THE MOSTcommon inflammatory disorder of thecentral nervous system (CNS), lead-ing to progressive neurological defi-cit.1 While most diseases of the CNS
display some degree of inflammation involving CNS-
resident innate immune cells (ie, microglia), MS is char-
acterized by the invasionof adaptive immune cells (ie, lym-
phocytes) into theCNSparenchyma. It is nowwidely held
that MS is an autoimmune disease in which encephalito-
genic myelin-reactive T lymphocytes invade the neuropil
and initiate an inflammatory cascade leading to demyelin-
ation and axonal loss. Current therapies for MS include
immunomodulatory drugs such as glatiramer acetate or
interferon , and while some degree of alleviation can be
achieved this way, we are still far away from a satisfactory
therapeutic effect.2 Rather than nonspecifically modulat-
ing immunity, an ideal therapeutic strategy would be to
specifically inhibit autoimmunitywhile preserving the im-
mune system’s protective function against microbes and
environmental hazards.One such specific approachwould
be to prevent inflammatory lymphocytes from entering
the CNS by preventing their transmigration across the
blood-brain barrier (BBB). Transmigration across endo-
thelial barriers (diapedesis) involves changes in the ex-
pression of adhesionmolecules on both blood vessels and
leukocytes (for review, see the article byMuller3). In 1992,
Yednock et al4 discovered that antibodies against 41
integrin (also known as very late activation antigen 4
[VLA-4]) can block the development of experimental au-
toimmune encephalomyelitis in mice. VLA-4 is upregu-
lated on inflammatory effector cells and binds to its li-
gand vascular cell adhesionmolecule 1,which is expressed
by vascular endothelial cells. Under the assumption that
the therapeutic intervention in mice specifically inhib-
ited the transmigration of pathogenic T cells across the
endothelial barrier, in the years after this discovery, a hu-
man anti–VLA-4 monoclonal antibody, natalizumab
(Tysabri; Elan Pharmaceuticals Inc, Dublin, Ireland), was
generated and patients with Crohn disease andMS were
treated. While clinical trials showed a drastic reduction
in the relapse rate in MS, 3 of 3000 patients developed
lethal progressivemultifocal leukoencephalopathy (PML).
Themanufacturer swiftly reacted and the drugwas taken
off the market pending further investigation. Why did
that happen? What went wrong?
Progressivemultifocal leukoencephalopathy is caused
by the reactivation of a latent polyomavirus JC infec-
tion. While the virus is well controlled in immunocom-
petent individuals, immunosuppressed individuals can-
not copewith this infection. Interestingly, the emergence
of PML in patients treated with natalizumab also pro-
vides insights into themechanistic underpinnings of this
therapeutic approach. It is conceivable that long-term in-
hibition of CNS immune surveillance leads to the un-
controlled growth of usually harmless pathogens such
as the JC virus. del Pilar Martin et al5 proposed that na-
talizumab therapy not only interferes with the transmi-
gration of pathogenic lymphocytes across the BBB but also
blocks the normal protective immune surveillance of the
CNS by preventing turnover of antigen-presenting cells
(APCs) associatedwithCNS vessels. They discovered that
the number of vessel-associated APCs and in particular
dendritic cells (DCs) is drastically reduced in patients
treatedwith natalizumab anddeveloping PML.This popu-
lation of CNS vessel–associated APCs was demon-
strated to be required and sufficient for the local antigen
recognition ofmyelin-reactive T cells in experimental au-
toimmune encephalomyelitis.6 When autoaggressive T
cells scan the CNS for their cognate antigens, it is the ves-
sel-associated DCs that license their entry into the neu-
ropil. The T cells cannot see their antigens if they are not
presented in the context ofmajor histocompatibility com-
plex molecules by a professional APC. Hence, in the ab-
sence of these gatekeepers, T cells are blind and fail to
invade the CNS. Clearly, in the context of autoimmu-
nity, eliminatingCNSvesselDCs is a highly efficient thera-
peutic strategy.On the other hand, under physiologic con-
ditions, the main purpose of these APCs is to sample
antigens locally throughphagocytosis and to present them
to T cells. Stüve et al7,8 recently discovered that natali-
zumab therapy drastically decreases the number of CD4
T cells in the cerebrospinal fluid of treated individuals.
Quite surprisingly, they found that the biological effects
of natalizumab last much longer than the pharmacologi-
cal half-life of the antibody. In other words, the paucity
of cerebrospinal fluid T cells 6 months after cessation of
treatment can hardly be explained by a direct effect of
natalizumab on the reentry of CD4 T cells.
The demonstrated long-lasting depletion of T cells from
the CNS can be explained by the slow turnover rate of
APCs from the BBB. If natalizumab therapy exhausts the
pool of BBB APCs, it would explain why T cells struggle
with CNS entry even after cessation of therapy. Only af-
ter the pool of these APCs is replenishedwill T cells again
be able to inspect the CNS.
See also page 1596
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While the observations presented by del Pilar Mar-
tin and colleagues are intriguing, the authors cannot
yet claim that the loss of vessel APCs is a direct effect
of the treatment. They have found this paucity of
APCs in postmortem tissue from patients with PML. It
is thus conceivable that it is not the treatment but the
pathogenesis of PML that leads to the death or expul-
sion of BBB DCs. However, this is not likely as the
numbers of DCs in CNS tissue of patients who died
from PML after an infection with the human immuno-
deficiency virus or a hematopoietic malignancy were
not decreased. Another limitation of this study is the
fact that no CNS tissue of patients treated with natali-
zumab who did not develop PML is currently available
for evaluation.
Whether natalizumab treatment directly influences the
entry of DCs through the vessels and thus dampens the
immune surveillance remains to be established. The chal-
lenges now are to delineate in detail the effect of natali-
zumab on immune surveillance and to develop tools to
monitor it in patients undergoing natalizumab therapy.
Lessons learned fromnatalizumab treatmentmay also ap-
ply to other therapies that are currently in development
or clinical trials, including rituximab, alemtuzumab, or
fingolimod (FTY720). All of these agents may affect an-
tigen presentation in and immune surveillance of theCNS
compartment.
Therapeutic interventions that are nowbecoming avail-
able were rationally designed with the pathogenesis of
MS in mind. These are good drugs. Perhaps it is time to
step back and reassess whether it is required to treat pa-
tients with MS indefinitely with some of these potent
agents.
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Announcement
New Initiatives: Clinical Trials andVideos.Wehave em-
barked on 2 new initiatives: Clinical Trials and video pre-
sentations.Wewelcomemanuscripts that describedouble-
blind, randomized, placebo-controlled clinical trials as our
primary area of interest. Open-label studies will also re-
ceive our special attention.We plan on expediting the re-
view process and time to publication and to include them
online ahead of print as these studies are time sensitive
and of direct benefit to our patients.Wehope youwill take
advantage of this new initiative. Please refer to the In-
structions for Authors when submitting a Clinical Trials
paper, including the requirement to register the trial with
an accepted clinical trials site.
We plan to utilize videos as part of published papers
that highlight and provide convincing information about
the observational and visual features of a patient’s neu-
rologic findings. Please refer to Instructions for Au-
thors for instructions on submitting video presentations.
Burkhard Becher, PhD
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